Health & Research Goals
Ipamorelin
Selective Growth Hormone Secretagogue
Primary Description
Ipamorelin is a pentapeptide (5 amino acids) that functions as a highly selective growth hormone secretagogue (GHS). It was the first compound in its class to demonstrate selective activation of the ghrelin receptor (GHSR-1a) for GH release without significantly affecting other pituitary hormones like ACTH, cortisol, or prolactin. It also demonstrates less appetite stimulation compared to other GH secretagogues like GHRP-6. Unlike non-selective GHRPs (GHRP-2, GHRP-6, hexarelin), Ipamorelin provides the benefits of GH optimization — recovery, muscle growth, fat loss, sleep — without hormonal disruption. Creates a predictable GH pulse peaking at ~40 minutes and declining to baseline by 6 hours. Mimics natural pulsatile GH release and preserves hypothalamic-pituitary feedback loops.
Key Benefits
- Increased GH release
- Minimal cortisol/prolactin effect
- Improved recovery
Lyophilized powder stable at room temperature; reconstituted vials should be refrigerated and used within 30 days.
Demonstrated Effects
- Selective GH release without cortisol or prolactin elevation
- Post-workout recovery acceleration and injury healing support
- Improved sleep efficiency and increased slow-wave sleep
- Lean muscle preservation and fat metabolism enhancement
- Increased bone mineral content and bone density improvement
- Enhanced IGF-1 production via liver GH conversion
- Metabolic rate optimization and improved muscle-to-fat ratio
Proposed Mechanisms of Action
Research Evidence & Clinical Data
Investigated Applications
Recovery & Healing
Anecdotal: HighPost-workout recovery acceleration, injury healing support, tissue repair enhancement, and reduced inflammation. Core component of the 'Recover Like Wolverine' stack combined with BPC-157, TB-500, Tesamorelin, and GHK-Cu.
Preclinical basis: GH-mediated IGF-1 production drives protein synthesis and muscle repair. Pulsatile GH release supports tissue regeneration pathways.
Sleep Optimization
Anecdotal: HighImproved sleep efficiency, increased slow-wave sleep, restoration of natural sleep patterns, and GH release during deep sleep. Recommended timing is right before bed within 30 minutes of sleep.
Preclinical basis: GH plays a critical role in deep sleep cycles. Ipamorelin's pulsatile GH release aligns with nocturnal GH secretion patterns.
Body Composition
Anecdotal: HighLean muscle preservation, fat metabolism enhancement, improved muscle-to-fat ratio, and metabolic rate optimization. Used in 'Lean and Mean' stack with IGF-1 LR3, CJC-1295, and Tesamorelin.
Preclinical basis: GH-stimulated lipolysis promotes fat breakdown. IGF-1 production supports anabolic muscle pathways. Dose-dependent response demonstrated in research.
Bone Health
Anecdotal: MediumIncreased bone mineral content, longitudinal bone growth (46 citations), bone density improvement, and osteoporosis prevention.
Preclinical basis: Landmark research by Raun et al. (1998) demonstrated ipamorelin's first selective GHRP-receptor agonist activity with bone density effects. GH activates osteoblasts for bone remodeling.
Anti-Aging & Longevity
Anecdotal: MediumMaintaining youthful GH levels, improved recovery, preservation of lean mass, and restoration of natural sleep patterns associated with aging decline.
Preclinical basis:
Scientific References
- 1.
- 2.Ipamorelin, the first selective growth hormone secretagogueEur J Endocrinol1998
Safety Profile
Common Side Effects
- Injection site reactions (redness, swelling) — common, mild
- Temporary water retention — mild
- Increased hunger — some users
- Mild headaches — usually transient
- Tingling sensations in extremities
- Severe injection site pain or abscess — rare
- Joint pain or swelling — rare
- Vision changes — rare
- Allergic reactions (rash, hives, difficulty breathing) — rare
- Minimal
- Headache (rare)
- Flushing (rare)
Contraindications
- Active cancer or recent cancer history (within past 5 years) — GH secretagogues may support tumor growth via IGF-1 pathway
- Pregnancy or breastfeeding — no safety data
- Uncontrolled diabetes — GH affects insulin sensitivity
- Family history of cancer — increased caution warranted
- Diabetic retinopathy — GH may worsen retinal conditions
- Carpal tunnel syndrome — GH can cause fluid retention
- Active malignancy
Research Protocols
Dosing Protocols
Monitoring & Risk Management
No Specific Monitoring Protocol
No structured monitoring data is available for this compound. Always consult a healthcare professional before use.